SBFM

Sunshine Biopharma, Inc.

$2.85

3.64%
SectorHealthcareIndustryDrug Manufacturers - Specialty & GenericCountryUnited States

Sunshine Biopharma, Inc. operates as a pharmaceutical company that engages in the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, dermatology, smoking cessation, cholelithiasis, anticonvulsant, urology, women's health, acid reflux, and anticonvulsant indications.

Source: Yahoo Finance
AI summary

Price & performance

1M-78.9%
3M-88.3%
YTD-98.2%
1Y-98.7%
52-week range—
Beta1.24
Full chart and returns against a benchmark

Q-Score

26/ 100

Quality against peers; 50 is the peer median.

Growth43
Risk14
Performance5
Valuation52
Profitability49
Leverage51
Sentiment—
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$36.3M+4.1%
Net income-$6M
Net margin-16.5%-1.7 pts
Historical fundamentals

Red flags in filings

2active red flags
Late filing noticeMar 31, 2026
Auditor changeSep 30, 2025
Filings, findings and the timeline

Revenue exposure

Regions, segments, customers and suppliers

Valuation

SBFMIndustryP/E—35.25P/S0.062.74EV/EBITDA—16.35P/B0.082.46PEG—0.87
Dividend yield0.00%
Every valuation metric